6MK Stock Overview

Operates as a healthcare company worldwide. More details

6MK fundamental analysis
Snowflake Score
Valuation	4/6
Future Growth	2/6
Past Performance	6/6
Financial Health	4/6
Dividends	5/6

Rewards

Trading at 59.3% below our estimate of its fair value

Earnings are forecast to grow 7.5% per year

Earnings grew by 4589.6% over the past year

Pays a reliable dividend of 3.43%

Risk Analysis

Shares are highly illiquid

Has a high level of debt

Community vs My Fair Value

Create Narrative

Select a narrative for quick price alerts from the community, or create your own.

Merck & Co., Inc. Competitors

AstraZeneca

LSE:AZN

UK£186.0b

Sopharma AD

BUL:SFA

лв964.9m

Novartis

SWX:NOVN

CHF 190.3b

Roche Holding

SWX:ROG

CHF 245.2b

Price History & Performance

Summary of share price highs, lows and changes for Merck
Historical stock prices
Current Share Price	US$87.80
52 Week High	US$98.20
52 Week Low	US$79.90
Beta	0.36
1 Month Change	5.28%
3 Month Change	-10.32%
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	35.65%

Recent updates

Shareholder Returns

	6MK	BG Pharmaceuticals	BG Market
7D	0%	-4.2%	0.9%
1Y	n/a	-4.7%	3.9%

Return vs Industry: Insufficient data to determine how 6MK performed against the BG Pharmaceuticals industry.

Return vs Market: Insufficient data to determine how 6MK performed against the BG Market.

Price Volatility

Is 6MK's price volatile compared to industry and market?
6MK volatility
6MK Average Weekly Movement	n/a
Pharmaceuticals Industry Average Movement	5.2%
Market Average Movement	3.7%
10% most volatile stocks in BG Market	6.9%
10% least volatile stocks in BG Market	2.3%

Stable Share Price: 6MK's share price has been volatile over the past 3 months compared to the BG market.

Volatility Over Time: Insufficient data to determine 6MK's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1891	74,000	Rob Davis	www.merck.com

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The company offers human health pharmaceutical for various areas, including oncology, vaccines, hospital acute care, cardiovascular, virology, neuroscience, and diabetes under the Keytruda, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, RotaTeq, Pneumovax 23, Bridion, Dificid, Zerbaxa, Noxafil, Winrevair, Adempas, Verquvo, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands.

Merck & Co., Inc. Fundamentals Summary

How do Merck's earnings and revenue compare to its market cap?
6MK fundamental statistics
Market cap	€219.51b
Earnings (TTM)	€15.73b
Revenue (TTM)	€58.96b

14.0x

P/E Ratio

3.7x

P/S Ratio

Is 6MK overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
6MK income statement (TTM)
Revenue	US$64.17b
Cost of Revenue	US$14.70b
Gross Profit	US$49.47b
Other Expenses	US$32.35b
Earnings	US$17.12b

Last Reported Earnings

Dec 31, 2024

Next Earnings Date

Apr 24, 2025

Earnings per share (EPS)	6.78
Gross Margin	77.09%
Net Profit Margin	26.68%
Debt/Equity Ratio	80.0%

How did 6MK perform over the long term?

See historical performance and comparison

Dividends

3.4%

Current Dividend Yield

46%

Payout Ratio

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/03/15 06:58
End of Day Share Price	2025/02/28 00:00
Earnings	2024/12/31
Annual Earnings	2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Merck & Co., Inc. is covered by 53 analysts. 22 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
David Toung	Argus Research Company
Fabrizio Spagna	Axia Financial Research
Ishan Majumdar	Baptista Research

6MK Stock Overview

Rewards

Risk Analysis

Merck & Co., Inc. Competitors

LSE:AZN

UK£186.0b

BUL:SFA

лв964.9m

SWX:NOVN

CHF 190.3b

SWX:ROG

CHF 245.2b

Price History & Performance

Recent News & Updates

Merck Announces Positive Data from Phase 3 Trials That Show the Investigational, Once-Daily, Oral, Two-Drug Regimen of Doravir/Islatravir Maintained HIV-1 Viral Suppression At Week 48

FDA Grants Priority Review to Merck’s Application for KEYTRUDA® (pembrolizumab) Plus Standard of Care as Perioperative Treatment for Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma

Merck Receives First European Commission Approval for Two Indications

Health Canada Approves Merck's KEYTRUDA® (Pembrolizumab) for the Treatment of Adult Patients with Respirable Non-Small Cell Lung Cancer

Independent Director recently bought €1.3m worth of stock

Merck Announces Phase 3 Waveline-010 Trial Initiation Evaluating Zilovertamab Vedotin, an Investigational Antibody-Drug Conjugate, for the Treatment of Patients with Previously Untreated Diffuse Large B-Cell Lymphoma

Recent updates

Merck Announces Positive Data from Phase 3 Trials That Show the Investigational, Once-Daily, Oral, Two-Drug Regimen of Doravir/Islatravir Maintained HIV-1 Viral Suppression At Week 48

FDA Grants Priority Review to Merck’s Application for KEYTRUDA® (pembrolizumab) Plus Standard of Care as Perioperative Treatment for Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma

Merck Receives First European Commission Approval for Two Indications

Health Canada Approves Merck's KEYTRUDA® (Pembrolizumab) for the Treatment of Adult Patients with Respirable Non-Small Cell Lung Cancer

Independent Director recently bought €1.3m worth of stock

Merck Announces Phase 3 Waveline-010 Trial Initiation Evaluating Zilovertamab Vedotin, an Investigational Antibody-Drug Conjugate, for the Treatment of Patients with Previously Untreated Diffuse Large B-Cell Lymphoma

Full year 2024 earnings released: EPS: US$6.74 (vs US$0.14 in FY 2023)

Merck & Co., Inc. Provides Earnings Guidance for the Full Year 2025

Merck Receives Positive EU CHMP Opinion for CAPVAXIVE (Pneumococcal 21-valent Conjugate Vaccine) for Pneumococcal Vaccination in Adults

Merck Announces Decision to Stop Phase 3 HYPERION Trial Evaluating WINREVAIR™ (sotatercept-csrk) Early and Move to Final Analysis

Merck Announces Second-Quarter 2025 Dividend, Payable on April 7, 2025

FDA Grants Priority Review to Merck's Application for WELIREG (belzutifan) for the Treatment of Patients with Advanced Pheochromocytoma and Paraganglioma (PPGL)

Merck and Eisai Provide Update on Phase 3 LEAP-015 Trial Evaluating KEYTRUDA (Pembrolizumab) Plus LENVIMA (Lenvima) in Combination with Chemotherapy in Patients with Certain Types of Gastroesophageal Adenocarcinoma

Merck’s GARDASIL® Receives Expanded Approval for Males in China

Merck Announces Topline Results from Pivotal Phase 3 Trials Evaluating Investigational, Once-Daily, Oral, Two-Drug, Single-Tablet Regimen of Doravirine/Islatravir (DOR/ISL) for the Treatment of Adults with Virologically Suppressed HIV-1 Infection

Merck Announces FDA Acceptance of Biologics License Application for Clesrovimab, an Investigational Long-Acting Monoclonal Antibody Designed to Protect Infants from RSV Disease During their First RSV Season

Merck & Co., Inc. Provides Update on KeyVibe and KEYFORM Clinical Development Programs Evaluating Investigational Vibostolimab and Favezelimab Fixed-Dose Combinations with Pembrolizumab

Merck Receives Positive EU CHMP Opinion for WELIREG®? (belzutifan) as Treatment for Adult Patients with Certain Types of Von Hippel-Lindau Disease-Associated Tumors and for Certain Previously Treated Adult Patients with Advanced Renal Cell Carcinoma

Merck Announces Phase 3 KEYLYNK-001 Trial Met Primary Endpoint of Progression-Free Survival (PFS) in Patients With Advanced Epithelial Ovarian Cancer

Merck & Co., Inc. Announces First Presentation of Data from the Phase 2 Waveline-007 Trial Evaluating Zilovertamab Vedotin

Insufficient new directors

Merck & Co., Inc. Announces Initiation of Phase 3 Study (MOVe-NOW) Evaluating LAGEVRIOTM (Molnupiravir) for the Treatment of Covid-19 in High-Risk Adults

Merck's Sacituzumab Tirumotecan Granted FDA Breakthrough Therapy Designation for Advanced EGFR-Mutated NSCLC

Merck Announces Pivotal Phase 3 Zenith Trial Evaluating Winrevair Met Primary Endpoint At Interim Analysis

Merck & Co., Inc. Appoints Surendralal L. Karsanbha to its Board of Directors, Effective January 1, 2025

Merck & Co., Inc.'s WELIREG (Belzutifan) Approves in China for the Treatment of Adult Patients with Certain Types of Von Hippel-Lindau (VHL) Disease-Associated Tumors

Merck Announces Phase 3 Trial of Subcutaneous Pembrolizumab with Berahyaluronidase Alfa Met Primary Endpoints

Merck Receives Positive EU CHMP Opinion for KEYTRUDA Plus Chemotherapy as First-Line Treatment for Adult Patients with Unresectable Non-Epithelioid Malignant Pleural Mesothelioma

Alexion, AstraZeneca Rare Disease and Merck Announces Positive Topline Results from the Phase 3 Komet Trial

Merck Announces Canada's Drug Agency Recommends WINREVAIR (sotatercept) for Reimbursement

Third quarter 2024 earnings released: EPS: US$1.24 (vs US$1.87 in 3Q 2023)

Merck and Moderna, Inc. Initiates Phase 3 Trial Evaluating Adjuvant V940 (mRNA-4157) in Combination with KEYTRUDA (Pembrolizumab) After Neoadjuvant KEYTRUDA and Chemotherapy in Patients with Certain Types of Non-Small Cell Lung Cancer (NSCLC)

CDC's ACIP Recommends Merck's CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine) for Pneumococcal Vaccination in Adults 50 Years of Age and Older

Merck's KEYTRUDA® (Pembrolizumab) Receives 30th Approval from European Commission with Two New Indications in Gynecologic Cancers